On the horizon: Promising investigational antiretroviral agents

Current Pharmaceutical Design

Volumn 12, Issue 9, 2006, Pages 1091-1103

  McNicholl, Ian R ^a   McNicholl, Joan J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral; Entry; HIV; Integrase; Investigational; Non nucleoside; Nucleoside; Protease

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; 3' FLUOROTHYMIDINE; 4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; 6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; AMD 070; AMDOXOVIR; ANTIRETROVIRUS AGENT; APLAVIROC; CAPRAVIRINE; CD4 IMMUNOGLOBULIN G2; DARUNAVIR; ELVUCITABINE; EMIVIRINE; ETRAVIRINE; MARAVIROC; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; PRO 140; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; TIPRANAVIR; TNX 355; UNINDEXED DRUG; VICRIVIROC; NEW DRUG;

ABDOMINAL PAIN; CLINICAL TRIAL; COMMON COLD SYMPTOM; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; FATIGUE; FEVER; FLATULENCE; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER DYSFUNCTION; NAUSEA; NONHUMAN; NOSE CONGESTION; PRIORITY JOURNAL; PRURITUS; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; URTICARIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VOMITING; ANIMAL; CLASSIFICATION; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; PHARMACEUTICS; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTI-RETROVIRAL AGENTS; DRUGS, INVESTIGATIONAL; HIV; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33645569644     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776055804     Document Type: Review

References (29)

1. Center for HIV Information, HIV InSite. Available at http://hivinsite.ucsf.edu. Accessed January 9, 2005. Report on the Global AIDS Epidemic, Executive Summary. UNAIDS, July 2004. Available at http://www.unaids.org/bangkok2004/GAR2004_html/ExecSummary_en/ ExecSumm_en_01.htm#P52_5995. Accessed January 9, 2005.
2. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-8.
3. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
4. Erickson-Viitanen S, Wu JT, Shi G, Unger S, King RW, Fish B, et al. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. Antivir Chem Chemother 2003; 14: 39-47.
5. Stuyver LJ, McBrayer TR, Schurmann D, Kravec I, Beard A, Cartee L, et al. Potent antiviral effect of Reverset in HIV-1-infected adults following a single oral dose. Antivir Ther 2004; 9: 529-36.
6. Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, et al. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′, 3′-dideoxy-2′, 3′-didehydro-5-fluorocytidine (Reverset). Antivir Chem Chemother 2003; 14: 49-59.
7. Gewwz BE, Jacobs M, Proper JA, Dahl TA, Fujiwara T, Dezube BJ. Capravirine, a nonnucleoside reverse transcriptase inhibitor in patients infected with HIV-1: a phase 1 study. J Infect Dis 2004; 190: 1957-61.
8. Bu H-Z, Pool WF, Wu EY, Raber SR, Amantea MA, Shetty BV. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Disp 2004; 32: 689-98.
9. Fujiwara T, Sato A, el-Farrash M, Miki S, Abe K, Isaka Y, et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1998; 42: 1340-5.
10. Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peeters M, Rineart A, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve, HIV-1 infected subjects. AIDS 2003; 17: 2487-94.
11. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, et al. An open-label assessment of TMC 125-a new, next generation NNRTI for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003; 17: 49-54.
12. Sankatsing SUC, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, et al. TMC125 eerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 2003; 17: 2623-27.
13. McCallister S, Valdez H, Curry K, MacGregor T, Borin M, Freimuth W, et al. A 14 day dose response study of the efficacy, safety and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naïve HIV-1 infected patients. J Acquir Immne Defic Syndr 2004; 35: 376-82.
14. King NM, Prabu-Jeyabalan M, Nalivaika EA, Wigerinck P, de Bethune MP, Schiffer CA. Structural and thermodynamic basis for the binding of TMC114, a next generation human immunodeficiency virus type 1 protease inhibitor. J Virol 2004; 78: 12012-21.
15. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286-91.
16. Shaheen F, Collman RG. Co-receoptor antagonists as HIV-1 entry inhibitors. Curr Op Infect Dis 2004; 17: 7-16.
17. Seibert C, Sakmar TP. Small-molecule antagonists of CCR5 and CXCR4: promising new class of anti HIV-1 drugs. Curr Pharm Des 2004; 10: 2041-62.
18. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. New advances in HIV entry inhibitors development. Curr Drug Targts Infect Disord 2004; 4: 339-55.
19. Markovic I, Clouse KA. Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention. Curr HIV Res 2004; 2: 223-34.
20. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004; 4: 965-77.
21. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem 2004; 4: 1059-77.
22. Middleton T, Lim HB, Montgomery D, Rockway T, Tang H, Cheng X, Lu L, et al. Inhibition of human immunodeficiency virus type I integrase by naphthamidines and 2-aminobenzimidazoles. Antiviral Res 2004; 64: 35-45.
23. Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004; 18: 2019-28.
24. Lee DJ, Robinson WE Jr. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid. J Virol 2004; 78: 5835-47.
25. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation. J Virol 2004; 78: 922-9.
26. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci USA 2003; 100: 13555-60.
27. Altmeyer R. Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des 2004; 10(30): 3701-12.
28. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 2004; 10(32): 4039-53.
29. Pereira CF, Paridaen JT. Anti-HIV drug development - an overview. Curr Pharm Des 2004; 10(32): 4005-37.